How the study of children with rheumatic diseases identified interferon‐α and interleukin‐1 as novel therapeutic targets
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Summary: Our studies in children with rheumatic diseases have led to the identification of two of the oldest cytokines, type I interferon (IFN) and interleukin 1 (IL‐1), as important pathogenic players in systemic lupus erythematosus (SLE) and systemic onset juvenile arthritis (SoJIA), respectively. These findings were obtained by studying the transcriptional profiles of patient blood cells and by assessing the biological and transcriptional effect(s) of active patient sera on healthy blood cells. We also identified a signature that can be used to promptly diagnose SoJIA from other febrile conditions. Finally, our pilot clinical trials using IL‐1 blockers have shown remarkable clinical benefits in SoJIA patients refractory to other medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Derivation of the sledai. A disease activity index for lupus patients
Bombardier, C., Gladman, D. D., Urowitz, M. B., Caron, D., Chang, C. H., Austin, A., Bell, A., Bloch, D. A., Corey, P. N., Decker, J. L., et al. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780350606 · Cited by 4,570
The Nature of the Principal Type 1 Interferon-Producing Cells in Human Blood
Siegal, F. P., Kadowaki, N., Shodell, M., Fitzgerald-Bocarsly, P. A., Shah, K., Ho, S., Antonenko, S., & Liu, Y.-J. (1999) · Science · doi:10.1126/science.284.5421.1835 · Cited by 2,293
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide
Lande, R., Gregorio, J., Facchinetti, V., Chatterjee, B., Wang, Y.-H., Homey, B., Cao, W., Wang, Y.-H., Su, B., Nestle, F. O., et al. (2007) · Nature · doi:10.1038/nature06116 · Cited by 1,910 · cited 3×
“LL37 converts inert self-DNA into a potent trigger of interferon production by binding the DNA to form aggregated and condensed structures that are delivered to and retained within early endocytic compartments in pDCs to trigger TLR9 (105).”
BackgroundInfluentialInterleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration
Pétrilli, V, Papin, S., Dostert, C., Mayor, A., Martinon, F., & Tschopp, J. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402195 · Cited by 1,445 · cited 1×
“Recently, a model in which K(1) efflux is the common and specific trigger of NALP1 and NALP3 activation induced by all reported ligands through the involvement of K(1) channel(s) has been proposed (133).”
BackgroundTian, J., Avalos, A. M., Mao, S.-Y., Chen, B., Senthil, K., Wu, H., Parroche, P., Drabic, S., Golenbock, D., Sirois, C., et al. (2007) · Nature Immunology · doi:10.1038/ni1457 · Cited by 1,372 · cited 1×
“This results in an amplification of this pathogenic loop (104).”
BackgroundJego, G., Palucka, A. K., Blanck, J.-P., Chalouni, C., Pascual, V., & Banchereau, J. (2003) · Immunity · doi:10.1016/s1074-7613(03)00208-5 · Cited by 1,067
Self-citationSutterwala, F. S., Ogura, Y., Szczepanik, M., Lara-Tejero, M., Lichtenberger, G. S., Grant, E. P., Bertin, J., Coyle, A. J., Galán, J. E., Askenase, P. W., et al. (2006) · Immunity · doi:10.1016/j.immuni.2006.02.004 · Cited by 980
Activation of the IL-1β-Processing Inflammasome Is Involved in Contact Hypersensitivity
Watanabe, H., Gaide, O., Pétrilli, V., Martinon, F., Contassot, E., Roques, S., Kummer, J. A., Tschopp, J., & French, L. E. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700819 · Cited by 416
The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling
Schoenemeyer, A., Barnes, B. J., Mancl, M. E., Latz, E., Goutagny, N., Pitha, P. M., Fitzgerald, K. A., & Golenbock, D. T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412584200 · Cited by 411 · cited 1×
“IRF5 is expressed in pDCs and B cells and seems to be a critical mediator of TLR7 signaling because (i) it is activated by TLR7/ 8 ligation and (ii) its ectopic expression enables type I IFN production in response to TLR7 ligands (85).”
Background
Cited by
Ravelli, A., & Martini, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60363-8 · Cited by 1,993
Prakken, B., Albani, S., & Martini, A. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60244-4 · Cited by 771
The role of defective clearance of apoptotic cells in systemic autoimmunity
Muñoz, L. E., Lauber, K., Schiller, M., Manfredi, A. A., & Herrmann, M. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.46 · Cited by 627
Prediction and Pathogenesis in Type 1 Diabetes
Ziegler, A.-G., & Nepom, G. T. (2010) · Immunity · doi:10.1016/j.immuni.2010.03.018 · Cited by 346
“On the basis of the array findings, a clinical trial of IL-1 blockade was initiated and rapidly led to its adoption as a therapy of choice for this patient group (Pascual et al., 2008).”
Targeting innate immunity protein kinase signalling in inflammation
Gaestel, M., Kotlyarov, A., & Kracht, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2829 · Cited by 316
Metadata
- Authors
- Pascual, V., Allantaz, F., Patel, P., Palucka, A. K., Chaussabel, D., & Banchereau, J.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2008-06
- Volume
- 223
- Issue
- 1
- Pages
- 39-59
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W2086209183
- Cited by
- 79
- References
- 14
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: How the study of children with rheumatic diseases identified interferon‐α and interleukin‐1 as novel therapeutic targets. https://app.cochat.ai/papers/10.1111/j.1600-065x.2008.00643.x
- The paper
- Pascual, V., Allantaz, F., Patel, P., Palucka, A. K., Chaussabel, D., & Banchereau, J. (2008). How the study of children with rheumatic diseases identified interferon‐α and interleukin‐1 as novel therapeutic targets. Immunological Reviews. https://doi.org/10.1111/j.1600-065x.2008.00643.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.